Core Viewpoint - Chengdu Yuandong Pharmaceutical Co., Ltd. has received the drug registration certificate for Arolol hydrochloride tablets, indicating compliance with drug registration requirements and marking a significant milestone for the company [1][5]. Drug Basic Information - Drug Name: Arolol hydrochloride tablets - Dosage Form: Tablets - Specification: 10mg - Registration Category: Class 4 chemical drug - Validity Period: 18 months - License Holder: Chengdu Yuandong Pharmaceutical Co., Ltd. - Production Company: Chengdu Yuandong Pharmaceutical Co., Ltd. - Registration Standard Number: YBH22152025 - Acceptance Number: CYHS2402067 - Certificate Number: 2025S02824 - Approval Document Number: Guoyao Zhunzi H20255424 - Approval Conclusion: The drug meets the registration requirements as per the Drug Administration Law of the People's Republic of China [1]. Drug Indications and Market Context - Arolol hydrochloride tablets are primarily indicated for primary hypertension (mild to moderate), angina pectoris, tachyarrhythmia, and essential tremor. - The drug was developed by Sumitomo Company in Japan and was first approved for sale in Japan in November 1985, with importation to China in August 1995. - It is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2024). - Domestic generic versions of Arolol hydrochloride tablets are already available from four companies: Shijiazhuang Grey Pharmaceutical, Beijing Xinnuo Kangqiao, Shandong Zhongjiankangqiao, and Beijing Fuyuan Pharmaceutical [2]. Sales Performance - According to data from key public hospitals in major provinces and cities, the sales amount of Arolol hydrochloride tablets in 2024 is approximately 144.55 million yuan, representing a year-on-year growth of 17.95% [3]. Impact on the Company - The approval of Arolol hydrochloride tablets, classified as a Class 4 chemical drug, signifies that the product has passed the consistency evaluation. However, the approval is not expected to have a significant impact on the company's short-term performance. The period from approval to production and sales may face uncertainties, and the company will fulfill its information disclosure obligations as required by law [5].

Core Points - The company, Yuandong Biological, announced the receipt of a drug registration certificate from the National Medical Products Administration for its product, Arolol Hydrochloride Tablets [2] Group 1 - The drug name approved is Arolol Hydrochloride Tablets [2] - The approval was granted by the National Medical Products Administration [2]

Core Viewpoint - Yuan Dong Biotech (688513.SH) has received the Drug Registration Certificate from the National Medical Products Administration for its product, Arolol Hydrochloride Tablets, which is indicated for primary hypertension (mild to moderate), angina pectoris, tachyarrhythmias, and essential tremor [1] Group 1 - The active ingredient of the newly approved drug is Arolol Hydrochloride [1] - The drug is primarily indicated for treating mild to moderate primary hypertension [1] - Additional indications include angina pectoris, tachyarrhythmias, and essential tremor [1]

成都苑东生物制药股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的《药品注册证书》，现将相关情 况公告如下： 一、药品基本情况 药品名称：盐酸阿罗洛尔片 剂型：片剂 证券代码：688513 证券简称：苑东生物 公告编号：2025-063 成都苑东生物制药股份有限公司 关于自愿披露盐酸阿罗洛尔片获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 规格：10mg 注册分类：化学药品 4 类 药品有效期：18 个月 上市许可持有人：成都苑东生物制药股份有限公司 生产企业：成都苑东生物制药股份有限公司 药品注册标准编号：YBH22152025 受理号：CYHS2402067 证书编号：2025S02824 药品批准文号：国药准字 H20255424 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生 ...

智通财经APP讯，苑东生物(688513.SH)公告，公司近日收到国家药品监督管理局核准签发的《药品注 册证书》，相关药品名称为：盐酸阿罗洛尔片。盐酸阿罗洛尔片主要活性成份为盐酸阿罗洛尔，主要适 应症为原发性高血压(轻度-中度)、心绞痛、心动过速性心律失常、原发性震颤。 ...

苑东生物(688513.SH)公告，公司近日收到国家药品监督管理局核准签发的《药品注册证书》，相关药 品名称为：盐酸阿罗洛尔片。盐酸阿罗洛尔片主要活性成份为盐酸阿罗洛尔，主要适应症为原发性高血 压(轻度-中度)、心绞痛、心动过速性心律失常、原发性震颤。 ...

Core Insights - The innovation drug industry in China is experiencing significant advancements in product research and development, with companies actively discussing their progress and strategies during the recent performance briefing session [1][2][3]. Group 1: Product Innovation and R&D Progress - Companies like Fudan Zhangjiang and Olin Bio are making notable advancements in their product pipelines, focusing on photodynamic therapy and vaccines for "super bacteria" [1][2]. - Fudan Zhangjiang is developing several drugs targeting conditions such as severe acne and bladder cancer, with ongoing clinical studies [2]. - Olin Bio is researching multiple vaccines for "super bacteria," aiming to initiate clinical trials for flu vaccines by mid-2025 [2]. Group 2: Business Expansion and Market Strategy - Companies are planning to expand their production capacity to support product commercialization, with Baiyao Tai focusing on launching several products that have completed Phase III clinical trials [3][4]. - Shian Bio is set to contribute significant revenue from its various vaccine products, including those for swine fever and other diseases [4]. Group 3: Internationalization and Market Entry - The trend of "going global" is a major focus for the domestic biopharmaceutical industry, with companies exploring diverse international pathways [5]. - Yuantong Bio is awaiting FDA approval for its naloxone nasal spray, marking a step towards international market entry [5]. - Aidi Pharmaceutical has received regulatory approval for its HIV treatment in Zanzibar, highlighting its international expansion efforts [6]. - Companies like Ailis and Haichuang Pharmaceutical are actively pursuing overseas partnerships and clinical trials to enhance their global presence [6][7].

Market Overview - The A-share market experienced fluctuations, with the Shanghai Composite Index down by 0.12%, the Shenzhen Component Index down by 0.43%, and the ChiNext Index down by 1.09% at the close [1] Sector Performance - The film and cinema sector saw a strong afternoon rally, with notable stocks like China Film hitting the daily limit, and others such as Golden Eagle Media and Happiness Blue Sea rising over 12% [3] - The semiconductor sector also performed well, with stocks like Chipone Technology hitting the daily limit and others like Beijing Junzheng rising over 10% [5] - The innovative drug concept showed signs of recovery, with stocks like Zhaoyan New Drug and Sairui Medical hitting the daily limit [8] - The titanium dioxide sector experienced a strong rally, with stocks like Zhenhua Holdings rising over 5% [9] Film Industry Insights - According to data from the National Film Administration, the total box office for the 2025 summer season in mainland China reached 11.966 billion yuan, with total audience numbers at 321 million, reflecting year-on-year growth of 2.76% and 12.75% respectively [3] - Analysts suggest that the steady growth in summer box office figures, along with the upcoming release of several major films, indicates a potential year-on-year increase in total box office revenue for the year [4] Semiconductor Industry Insights - TSMC reported a revenue of 335.77 billion New Taiwan dollars for August 2025, marking a year-on-year increase of 33.8% and a quarter-on-quarter increase of 3.9% [6] - According to Guotou Securities, the global semiconductor industry maintained high prosperity in the first half of the year, with the Chinese sector performing particularly well. The industry is expected to continue its "AI-driven + self-controllable" dual development trend in the second half of the year [7] Pharmaceutical Sector Developments - In the Hong Kong market, the stock of Yaojie Ankang-B surged nearly 120% following the announcement of clinical trial approval for its core product Tinengotinib for breast cancer treatment [10] - Kangfang Biopharma's stock rose over 6% after updates on its AK112 clinical trial showed successful results in achieving the primary endpoint of progression-free survival [10] - Alibaba's stock increased over 5% after the release of its next-generation model architecture Qwen3-Next, which includes significant improvements over its previous model [10] ETF Performance - The Hang Seng Medical ETF, which tracks the Hang Seng Hong Kong-listed Biotechnology Index, saw a recent increase of 1.49% over the past five days, with a net inflow of 19.27 million yuan [13]

Market Overview - The A-share market experienced fluctuations, with the Shanghai Composite Index down 0.12%, Shenzhen Component down 0.43%, and ChiNext down 1.09% at the close [2] - The film and semiconductor sectors showed strong performance, while insurance, liquor, and banking sectors faced declines [2] Film Industry - The film sector saw a late surge, with China Film hitting the daily limit and achieving three consecutive gains over six days, while other companies like Golden Shield Film and Happiness Blue Sea also saw significant increases [3] - According to the National Film Administration, the total box office for the 2025 summer season in mainland China reached 11.966 billion yuan, with total attendance at 321 million, marking year-on-year growth of 2.76% and 12.75% respectively [5] - Analysts expect continued growth in the film box office for the year, driven by the release of several major films [5] Semiconductor Industry - The semiconductor sector was notably strong, with Chipone Technology hitting the daily limit and companies like Sai Microelectronics and Beijing Junzheng rising over 10% [5] - TSMC reported a revenue of 335.77 billion New Taiwan dollars for August 2025, reflecting a year-on-year increase of 33.8% and a quarter-on-quarter increase of 3.9% [7] - The global semiconductor industry remains robust, with China's sector performing particularly well, and the industry is expected to continue its "AI-driven + self-controllable" dual development strategy in the second half of the year [7] Pharmaceutical Sector - In the Hong Kong market, the stock of Drug Innovation Technology surged nearly 120% following the announcement of clinical trial approval for its core product Tinengotinib for breast cancer treatment [9] - Kangfang Biologics saw a rise of over 6% after updates on its AK112 clinical trial, which successfully met its primary endpoint for progression-free survival [9] Other Notable Stocks - Alibaba's stock increased by over 5% after the release of its next-generation model architecture Qwen3-Next, which includes significant improvements over its previous model [9]

Market Overview - The three major indices in the market closed lower, with the Shanghai Composite Index down 0.12%, the Shenzhen Component Index down 0.43%, and the ChiNext Index down 1.09% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 2.52 trillion yuan, an increase of 83.2 billion yuan compared to the previous trading day, with over 3,300 stocks declining [2] Sector Performance Innovative Pharmaceuticals - The innovative pharmaceutical sector showed strong performance, with notable stocks like Yaoke Ankang-B surging by 116%, reaching a market capitalization of over 90 billion yuan [3][6] - Other pharmaceutical stocks such as Nuocheng Jianhua and Yuandong Bio also saw significant gains, with increases of over 12% and 11% respectively [3] Storage Chips - The storage chip sector experienced a notable rise, with stocks like Chipone Technology hitting the daily limit of 20% [11] - Other companies in this sector, including Jingzhida and Beijing Junzheng, also saw increases of over 14% and 10% respectively [11][12] Non-ferrous Metals - The non-ferrous metals sector led the market, with silver futures breaking the 10,000 yuan per kilogram mark [17][21] - Companies such as Electric Alloy and Shengda Resources saw their stock prices rise by 20% and 10.02% respectively, indicating strong market interest [18][20] Company-Specific Developments Yaoke Ankang-B - Yaoke Ankang-B's core product, Tinengotinib, received approval for a Phase II clinical trial for breast cancer, contributing to its stock surge [9] - Despite the stock price increase, the company's financial report for the first half of 2025 showed zero revenue, with a loss of 123 million yuan [9][10] Chipone Technology - Chipone Technology announced a significant acquisition, planning to purchase 97.0070% of Chipai Technology, which will enhance its capabilities in the RISC-V field [15] - The company reported a record high in new orders, amounting to 12.05 billion yuan, a year-on-year increase of 85.88% [16] Non-ferrous Metals - The non-ferrous metals sector is driven by macro liquidity, industrial policies, and geopolitical factors, with a focus on supply-demand balance for industrial metals like copper and aluminum [21]